featured
Efficacy and Safety of Extended-Duration Letermovir Prophylaxis in HSCT Recipients at Risk for Cytomegalovirus Infection
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Haematol 2023 Dec 21;[EPub Ahead of Print], D Russo, M Schmitt, S Pilorge, M Stelljes, T Kawakita, VL Teal, B Haber, C Bopp, SS Dadwal, C BadshahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.